Compare Danaher Corporation (DHR) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Marsh & McLennan Companies, Inc. — how do they compare? Danaher Corporation trades at $207.17 (market cap $145.83B), while Marsh & McLennan Companies, Inc. trades at $189.03 (market cap $91.27B). The key difference: Danaher Corporation is the larger of the two by market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.07%). Which is the better fit depends on your goals.
| DHR | MRSH | |
|---|---|---|
Market Cap | $145.83B | $91.27B |
Sector | Health | Financials |
52-Week High | $242.05 | $211.21 |
52-Week Low | $161.91 | $157.32 |
Enterprise Value | $168.04B | $111.95B |
Dividend Yield | 0.77% | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Marsh & McLennan (MRSH) trades at $189.13, down 0.87% on the day, with a bullish technical signal and strong fundamental performance. Recent earnings beats in Q2 2026, with EPS of $2.96 versus $2.88 expected, and 6% revenue growth highlight operational strength. The company announced the acquisition of Accel to expand its Midwest insurance reach, signaling strategic growth. Valuation metrics show a P/E of 23.35 and robust profitability with a net income margin of 14.24%.
The outlook remains positive with a consensus price target of $202.89, offering potential upside. Risks include margin pressure from rising expenses and soft P&C pricing. Institutional activity is mixed, with Bank of America reducing its stake while others like Bank of Nova Scotia increased holdings. The stock presents a solid long-term growth opportunity amid cyclical insurance sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
